- Home
- RAPP
as of 03-19-2026 3:56pm EST
$27.37
$0.09
-0.33%
Stocks Nasdaq
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.3B | IPO Year: | 2024 |
| Target Price: | $48.50 | AVG Volume (30 days): | 292.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | 24.34 |
| 52 Week Low/High: | $7.73 - $42.27 | Next Earning Date: | 03-10-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -9.57 | Index: | N/A |
| Free Cash Flow: | -88089000.0 | FCF Growth: | N/A |
AI-Powered RAPP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 14 hours ago
AI Recommendation
hold
Model Accuracy: 73.85%
73.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Rapport Therapeutics Inc. (RAPP)
Gault Cheryl
Sell
Chief Operating Officer
RAPP Mar 5, 2026
Avg Cost/Share
$28.93
Shares
2,014
Total Value
$58,265.02
Owned After
169,914
SEC Form 4
Ceesay Abraham
Sell
Chief Executive Officer
RAPP Jan 20, 2026
Avg Cost/Share
$26.11
Shares
10,916
Total Value
$285,070.92
Owned After
562,080
Bredt David
Sell
Chief Scientific Officer
RAPP Jan 15, 2026
Avg Cost/Share
$27.11
Shares
8,500
Total Value
$228,131.65
Owned After
395,575
Bredt David
Sell
Chief Scientific Officer
RAPP Dec 31, 2025
Avg Cost/Share
$30.05
Shares
6,567
Total Value
$197,337.69
Owned After
395,575
SEC Form 4
Yeleswaram Krishnaswamy
Sell
Chief Development Officer
RAPP Dec 31, 2025
Avg Cost/Share
$30.05
Shares
2,840
Total Value
$85,342.00
Owned After
296,991
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gault Cheryl | RAPP | Chief Operating Officer | Mar 5, 2026 | Sell | $28.93 | 2,014 | $58,265.02 | 169,914 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Jan 20, 2026 | Sell | $26.11 | 10,916 | $285,070.92 | 562,080 | |
| Bredt David | RAPP | Chief Scientific Officer | Jan 15, 2026 | Sell | $27.11 | 8,500 | $228,131.65 | 395,575 | |
| Bredt David | RAPP | Chief Scientific Officer | Dec 31, 2025 | Sell | $30.05 | 6,567 | $197,337.69 | 395,575 | |
| Yeleswaram Krishnaswamy | RAPP | Chief Development Officer | Dec 31, 2025 | Sell | $30.05 | 2,840 | $85,342.00 | 296,991 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 10, 2026 · 99% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 10, 2026 · 99% conf.
AI Prediction SELL
1D
-2.38%
$30.05
Act: +3.07%
5D
-8.43%
$28.19
20D
+0.95%
$31.07
Price: $30.78 Prob +5D: 0% AUC: 1.000
0001193125-26-099336
8-K
false000201259300020125932026-03-102026-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2026
Rapport Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-42121
88-0724208
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
99 High Street Suite 2100
Boston, Massachusetts
02110
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (857) 321-8020
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
RAPP
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 10, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by Rapport Therapeutics, Inc. on March 10, 2026, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Rapport Therapeutics, Inc.
Date:
March 10, 2026
By:
/s/ Troy Ignelzi
Troy Ignelzi Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 6, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 6, 2025 · 100% conf.
AI Prediction SELL
1D
-3.38%
$24.65
Act: +0.59%
5D
-10.18%
$22.91
Act: -3.29%
20D
-3.94%
$24.50
Act: +15.64%
Price: $25.51 Prob +5D: 0% AUC: 1.000
0001193125-25-268072
8-K
0002012593false00020125932025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 06, 2025
Rapport Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-42121
88-0724208
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
99 High Street Suite 2100
Boston, Massachusetts
02110
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (857) 321-8020
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
RAPP
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by Rapport Therapeutics, Inc. on November 6, 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Rapport Therapeutics, Inc.
Date:
November 6, 2025
By:
/s/ Troy Ignelzi
Troy Ignelzi Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-104557
8-K
0002012593false00020125932025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
Rapport Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-42121
88-0724208
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
99 High Street Suite 2100
Boston, Massachusetts
02110
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (857) 321-8020
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
RAPP
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On August 7, 2025, the Company posted to the “News & Events—Presentations” section of investor relations page of the Company’s website at investors.rapportrx.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is furnished hereto as Exhibit 99.2 to this Current Report on Form 8-K.
The information included under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by Rapport Therapeutics, Inc. on August 7, 2025, furnished herewith.
99.2
Corporate Presentation, dated August 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Rapport Therapeutics, Inc.
Date:
August 7, 2025
By:
/s/ Troy Ignelzi
Troy Ignelzi Chief Financial Officer
Latest Rapport Therapeutics Inc. News
RAPP Breaking Stock News: Dive into RAPP Ticker-Specific Updates for Smart Investing
Motley Fool
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
📈
AI Sentiment
Highly Positive
8/10
Compare RAPP vs Leading Stocks
See how RAPP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RAPP Rapport Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.